pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

CURIUM

USupdated 2mo ago
community read0 votes
pipeline
9
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(9)

pipeline depth9 products
Unknown: 9
9Unknown
drug
IOFLUPANE I 123
drug
SODIUM IODIDE I 123
drug
TECHNESCAN HDP
drug
TECHNESCAN PYP
drug
TECHNETIUM TC 99M SESTAMIBI
drug
THALLOUS CHLORIDE TL 201
drug
ULTRA-TECHNEKOW V4
drug
ULTRATAG RBC
drug
XENON, XE-133

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view CURIUM jobs →

News

  • Curium buys radiopharma rival Lantheus for $8B; Sandoz settles price-fixing case
    ☢️ Curium spends $8B for Lantheus: Curium is buying fellow radiopharma company Lantheus for $102.5 per share. Lantheus shareholders may receive $12 more per share if certain targets are achieved ...
    endpoints · 10h ago
  • Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
    Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
    biospace · 11h ago
  • Curium strikes up to $8B deal for radiopharma rival Lantheus
    Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
    fiercebiotech · 11h ago
  • Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug
    Plus, news about West Pharmaceutical, Stallergenes Greer and Curium: 🏭 Hikma’s US expansion: The generic drugmaker is investing $267 million in Ohio. Its existing factory in Columbus will get $216…
    endpoints · 2mo ago
identifiers
country
US
source
openfda_drugsfda
mentioned in
4news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?